Bcl-2 antisense therapy in multiple myeloma.

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Malignant plasma cells in multiple myeloma (MM) often overexpress Bcl-2, conferring resistance to chemotherapy.
• Bcl-2 protein promotes cell survival and contributes to multidrug resistance in MM.

Purpose of the Study:

• To evaluate oblimersen sodium, an antisense oligonucleotide targeting bcl-2 mRNA, as a strategy to reverse chemotherapy resistance in MM.
• To assess the efficacy and safety of oblimersen in combination with standard MM therapies.

Main Methods:

• Oblimersen sodium administration to human myeloma cell lines and ex vivo purified myeloma cells.
• Phase II clinical trials combining oblimersen with dexamethasone/thalidomide or vincristine/doxorubicin/dexamethasone.
• Phase III randomized trial comparing dexamethasone plus oblimersen versus dexamethasone alone in relapsed/refractory MM.

Main Results:

• Oblimersen sodium reduced Bcl-2 protein production and enhanced the cytotoxicity of dexamethasone and doxorubicin.
• Preliminary Phase II data indicated that oblimersen combinations were active and well-tolerated in relapsed/refractory MM.
• Oblimersen demonstrated potential in overcoming chemotherapy resistance and restoring MM cell sensitivity.

Conclusions:

• Oblimersen sodium represents a promising therapy-enhancing strategy for multiple myeloma.
• Combination therapy with oblimersen may overcome multidrug resistance and improve treatment outcomes in MM patients.
• Further investigation, including combination with novel agents like bortezomib, is warranted.